The company’s Q3 results and announced deal with Novartis (NVS) involving both a research and expanded software utilization collaboration drove the stock higher, and while operating results from the ...

Purpose-led collaboration is not just a buzzword; it is a strategic approach where all stakeholders come together with a ...

While statins can reduce LDL levels and ASCVD events, high Lp(a) poses an independent risk that will need attention, too.

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Schrodinger (SDGR – Research Report), with a ...

Sandoz Inc., Pfizer Inc., and Amneal Pharmaceuticals Inc. are among a group of generic-drug manufacturers that will face some ...

Novartis (NVS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

In February, Takeda signed an MoU on rare diseases with the Medical Services Administration under the Ministry of Health, in ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Alcon, whose biggest market is the U.S. making up nearly a half of its revenue, said it expected annual net sales to grow by ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four ...